Revisiting bleomycin from pathophysiology to safe clinical use.

@article{Froudarakis2013RevisitingBF,
  title={Revisiting bleomycin from pathophysiology to safe clinical use.},
  author={Marios E Froudarakis and Eleftheria Hatzimichael and Lydia Kyriazopoulou and Konstantinos G Lagos and Periklis Pappas and Andreas G. Tzakos and Vasilis Karavasilis and Danai D. Daliani and Christos Papandreou and Evangelos Briasoulis},
  journal={Critical reviews in oncology/hematology},
  year={2013},
  volume={87 1},
  pages={90-100}
}
Bleomycin is a key component of curative chemotherapy regimens employed in the treatment of curable cancers, such as Hodgkin lymphoma (HL) and testicular germ-cell tumours (GCT), yet its use may cause bleomycin-induced lung injury (BILI), which is associated with significant morbidity and a mortality rate of 1-3%. Diagnosis of BILI is one of exclusion and physicians involved in the care of HL and GCT patients should be alerted. Pharmacogenomic studies could contribute towards the identification… CONTINUE READING